Nano Dimension (NNDM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Jun, 2026Executive summary
Murchinson Ltd. and affiliates, holding 7.7% of shares, are soliciting proxies to enact significant governance changes at an extraordinary general meeting, citing underperformance and poor governance.
The meeting agenda includes proposals to declassify the board, require shareholder approval for poison pills and major transactions, remove three directors, and appoint three new nominees.
Murchinson recommends voting for all its proposals, aiming to align the board with shareholder interests and enhance accountability.
Voting matters and shareholder proposals
Proposals include a non-binding advisory vote on the company's strategic alternatives review, declassification of the board, restrictions on poison pills, shareholder approval for major transactions, removal of three directors, and appointment of three new directors.
Each proposal has specific approval thresholds, with most requiring a simple majority, except the board declassification, which requires a 70% majority.
Shareholders can vote by proxy, with detailed procedures for ADS and ordinary share holders.
Board of directors and corporate governance
Proposal to amend Article 39 to declassify the board and require annual director elections.
Proposal to remove directors Robert Pons, Joshua Rosensweig, and David Stehlin, and any new directors appointed after May 21, 2026.
Proposal to appoint Moshe Rozenbaum, Eliezer Eli Tarlow, and Paul Fruchthandler as new directors, who are presented as independent and highly qualified.
Latest events from Nano Dimension
- Proposed merger with Infinite Epigenetics offers a 20% premium and pivots to AI-powered diagnostics.NNDM
Proxy filing17 Jun 2026 - $890M merger forms a Nasdaq-listed AI diagnostics leader targeting the $90–94B U.S. market.NNDM
M&A announcement16 Jun 2026 - Nano and Infinite plan a merger to create an AI-powered health diagnostics company, pending approvals.NNDM
Proxy filing15 Jun 2026 - Board supports declassification but opposes director removal and other governance changes.NNDM
Proxy filing11 Jun 2026 - Shareholders will vote on strategic direction, board structure, and director changes amid a proxy contest.NNDM
Proxy filing5 Jun 2026 - Strategic plan advances with cost cuts, asset sales, and a pivotal shareholder vote ahead.NNDM
Proxy filing5 Jun 2026 - Board opposes activist director replacements, prioritizing strategic review and shareholder value.NNDM
Proxy filing26 May 2026 - Q1 2026 revenue surged 106% year-over-year, but net loss deepened amid restructuring and impairment.NNDM
Q1 20267 May 2026 - 2025 revenue up 77% to $102.4M, Q4 up 142%, with 2026 guidance for 30%+ growth.NNDM
Q4 202531 Mar 2026